Application of dioscin serving as active ingredient of Chinese yam in preparation of medicine for improving acute lung injury

By using the yam active ingredient DISAPENS, the expression of SIRT1 is promoted, the acetylation and oxidative stress of HMGB1 is inhibited, and the cell autophagy is promoted, which solves the effectiveness and safety of acute lung injury treatment, and significantly improves the symptoms of acute lung injury and the lungs. Tissue damage degree.

CN118924778APending Publication Date: 2024-11-12YANBIAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411200213.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Acute lung injury (ALI) and its severe forms of acute respiratory distress syndrome (ARDS) lack effective treatments, there are adverse reactions in existing drug treatments, and the incidence of acute lung injury has increased year by year, bringing huge pressure to human health and health systems .

Method used

Dioscin, an active ingredient in yam, is used to promote SIRT1 expression, inhibit the acetylation of HMGB1, inhibit LPS-induced oxidative stress in cells, promote cell autophagy, and thus improve acute lung injury.

Benefits of technology

Diosperm can dosagely promote SIRT1 expression, inhibit the acetylation of HMGB1, inhibit the oxidative stress of LPS induces cell induced by LPS, promote cell autophagy, significantly improve acute lung injury, and reduce inflammation, proving that it is effective in treating inflammatory acute lung injury. drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924778A_ABST
    Figure CN118924778A_ABST
Patent Text Reader

Abstract

The invention discloses application of dioscin serving as an active ingredient of Chinese yam in preparation of a medicine for improving acute lung injury, and belongs to the technical field of application of natural small molecule medicines. The invention provides application of dioscin (Dio) serving as an active ingredient of Chinese yam in preparation of a medicine for improving acute lung injury. The invention provides a medicine for treating, preventing or improving acute lung injury. The medicine comprises dioscin serving as an active ingredient of Chinese yam. The invention also provides an application of the Chinese yam active component dioscin in preparation of an SIRT1 expression agonist. The Chinese yam active component dioscin can promote expression of SIRT1 in LPS-induced macrophages in a dosage manner. The invention further provides application of the yam active ingredient dioscin in preparation of an inhibitor for acetylation of HMGB1 (High Mobility Group Box 1) in cells. According to the application disclosed by the invention, the active ingredient dioscin of the Chinese yam can dose-wise promote expression of SIRT1 in LPS-induced macrophages and inhibit acetylation of HMGB1, so that the acute lung injury is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of application of natural small molecule drugs, and in particular relates to the application of diosgenin, an active ingredient of yam, in the preparation of drugs for improving acute lung injury. Background Art

[0002] Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are primarily associated with uncontrolled, overwhelming inflammatory lung injury with a high mortality rate of 35%-46%. Another global literature survey reported a mortality rate of 45% for COVID-19-related ARDS, with the incidence of ARDS in non-COVID-19 survivors soaring to 90%, characterized by non-cardiogenic pulmonary edema, hypoxemic respiratory failure, and increased vascular permeability due to the presence of protein-rich exudates and neutrophil infiltration in the alveolar spaces. Recently, severe influenza infection with lung epithelial damage and endothelial dysfunction has been widely recognized to contribute to ALI, and there is no specific drug treatment for ALI / ARDS in patients with severe influenza. Current treatment options mostly use drugs such as dexamethasone and prednisone to reduce inflammation and suppress respiratory failure, which can cause various adverse effects, including coagulopathy, gastric ulcers, or osteoporosis. Although ALI has been extensively studied for decades, no effective treatment has been developed. Therefore, there is a great demand for the development of new drugs to treat ALI / ARDS. In summary, acute lung injury is a common and destructive inflammatory disease of the respiratory system, with an increasing incidence rate year by year, which seriously endangers human life and health and imposes a heavy burden on the health system.

[0003] SIRT1 is a class III histone deacetylase that is widely present in the nuclei of various somatic cells and germ cells in the body. SIRT1 is mainly composed of two basic structures, one large and one small: the large domain is mainly composed of the Rossmann fold pattern and is highly conserved; the small domain contains a zinc ribbon structure and a helical component, which is less conserved. Although SIRT1 is mainly located in the nucleus, endogenous and exogenous SIRT1 can transfer between the cytoplasm and the nucleus, and play an important regulatory role in anti-oxidative stress, inhibition of inflammatory response, energy metabolism, cell apoptosis, autophagy, etc. by regulating nucleosomal histone acetylation and the activity of various transcription factors. SIRT1 can deacetylate histones and non-histones. Studies have shown that SIRT1 activation promotes HMGB1 deacetylation. Recent studies have confirmed that SIRT1 can deacetylate Beclin1, thereby activating Beclin1 and promoting cell autophagy. SIRT1 also deacetylates other autophagy-related proteins (Atg5, Atg7 and LC3), thereby promoting autophagy and cell and tissue repair.

[0004] The toxicity and symptom recurrence of currently available synthetic drugs upon withdrawal are inevitable key issues, and the development of safer anti-inflammatory drugs remains a topic of great concern. Natural products with medicinal and edible properties are safe, effective, biocompatible and cost-effective candidates for the treatment of inflammatory diseases, and traditional Chinese medicine has officially entered the international mainstream medical classification system. Chinese yam (CY), also known as yam, is a traditional Chinese medicinal material with medicinal and edible properties. It does not contain any harmful substances and is the king of green health foods in the world today. According to statistics, yam contains 16 kinds of amino acids required by the human body. Dioscin (Dio) is the main active ingredient of yam, which is composed of spirostane-type diosgenin and sugar chains connected by glycosidic bonds, accounting for 0.6%-1.0% in yam dry powder. In recent years, the pharmacological research on dioscin has mainly focused on regulating immunity, anti-tumor, anti-inflammatory analgesia, and protecting gastrointestinal mucosa. However, the mechanism by which dioscin targets STRT1 to fight acute liver injury is still unclear. Therefore, in-depth exploration of dioscin targeting STRT1 to alleviate inflammatory response has become a new direction for the treatment of acute lung injury. Summary of the invention

[0005] In order to solve the above technical problems, the present invention proposes the use of dioscin (Dio), an active ingredient of yam, in the preparation of a drug for improving acute lung injury. Dioscin, an active ingredient of yam, can promote the expression of SIRT1 in LPS-induced macrophages, inhibit the acetylation of HMGB1, inhibit the oxidative stress of LPS-induced cells, promote LPS-induced cell autophagy, and thus improve acute lung injury.

[0006] To achieve the above object, the present invention provides the use of dioscin, an active ingredient of yam, in the preparation of a drug for improving acute lung injury.

[0007] Preferably, the yam active ingredient dioscin is used to treat, prevent or improve acute lung injury.

[0008] Preferably, the yam active ingredient dioscin improves acute lung injury by promoting SIRT1 expression, inhibiting the acetylation of HMGB1, inhibiting LPS-induced cellular oxidative stress, and promoting LPS-induced cellular autophagy.

[0009] Further preferably, the yam active ingredient dioscin can promote the expression of SIRT1 in LPS-induced macrophages in a dose-dependent manner.

[0010] The present invention also provides the use of the yam active ingredient dioscin in preparing a medicine for treating, preventing or improving LPS-induced acute lung injury.

[0011] The present invention also provides a medicine for treating, preventing or improving acute lung injury, comprising the yam active ingredient dioscin.

[0012] The present invention also provides the use of the yam active ingredient dioscin in the preparation of a SIRT1 expression agonist.

[0013] Preferably, the yam active ingredient dioscin can promote the expression of SIRT1 in LPS-induced macrophages in a dose-dependent manner.

[0014] The present invention also provides a SIRT1 expression agonist, comprising the yam active ingredient dioscin.

[0015] The present invention also provides the use of the yam active ingredient dioscin in preparing an HMGB1 acetylation inhibitor in cells.

[0016] Compared with the prior art, the present invention has the following advantages and technical effects:

[0017] In view of this, the purpose of the present invention is to provide the use of dioscin (Dio), an active ingredient of yam, in the preparation of a drug for promoting SIRT1 to improve acute lung injury; the dioscin (Dio) can promote the expression of SIRT1 in LPS-induced macrophages in a dosed manner, inhibit the acetylation of HMGB1, inhibit the oxidative stress of LPS-induced cells, promote LPS-induced cell autophagy, and thus improve acute lung injury.

[0018] The present invention proves that dioscin, the active ingredient of yam, can improve acute lung injury by promoting SIRT1 expression in LPS-induced macrophages in a dosed manner, inhibiting HMGB1 acetylation in LPS-induced macrophages, inhibiting oxidative stress in LPS-induced macrophages, promoting LPS-induced cell autophagy-related protein P62, LC3A-B, Beclin1 expression, promoting autophagy and reducing inflammation. It shows that dioscin can be used as a drug for treating inflammatory acute lung injury, and proves that dioscin can improve the degree of injury and the dry-wet ratio of mouse lung tissue in acute lung injury mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0020] Figure 1ELISA method was used to detect the effect of dioscin on the expression of inflammatory factors in LPS-induced macrophages, where A is IL-1β, B is IL-16, and C is TNF-α. In the figure, "###" represents P<0.001 vs. CTR, "**" represents P<0.01 vs. LPS, and "***" represents P<0.001 vs. LPS, (n=3);

[0021] Figure 2 Western blotting was used to detect the effect of dioscin on the acetylation of HMGB1 in macrophages, where A is the expression of HMGB1 in the nucleus and cytoplasm, in the figure, Nucleus-HMGB1 represents the situation of HMGB1 in the nucleus, Histone represents the internal reference of the nucleus, Cytoplasm-HMGB1 represents the expression of HMGB1 in the cell, HMGB1 represents the expression of HMGB1, β-actin represents the internal reference, B is the effect of dioscin on SIRT1, Acetylated-HMGB1 and HMGB1, in the figure, SIRT1 represents silent information regulator 1, Acetylated-HMGB1 represents acetylated high-mobility group protein B1, HMGB1 represents high-mobility group protein B1, and β-actin represents the internal reference;

[0022] Figure 3 The reactive oxygen species detection kit was used to detect the effect of dioscin on the content of ROS in macrophages;

[0023] Figure 4 The mitochondrial membrane potential detection kit was used to detect the effect of dioscin on the mitochondrial membrane potential of macrophages. In the figure, Aggregate represents the red fluorescence produced by the polymer, Monomer represents the green fluorescence produced by the monomer, Merge represents the merger of red fluorescence and green fluorescence, Contorl represents the control group, LPS represents the model group, LPS+Dio (1μM) represents the drug administration group, and LPS+NAC (0.5nM) represents the positive drug group;

[0024] Figure 5 Western blotting was used to detect the effect of dioscin on the expression of autophagy-related proteins in macrophages;

[0025] Figure 6Western blotting was used to detect the effect of dioscin on cellular HMGB1 acetylation, oxidative stress and autophagy through SIRT. A is the effect of dioscin on HMGB1-related proteins in macrophages. In the figure, SIRT1 represents silent information regulator, Cytoplasm-HMGB1 represents the expression of HMGB1 in the cytoplasm, HMGB1 represents high mobility group protein B1, Acetylated-HMGB1 represents acetylated high mobility group protein B1, β-actin represents the internal reference, and B is the effect of dioscin on inflammation-related proteins in macrophages. In the figure, p-NF-kB p65 represents phosphorylated nuclear factor-κB, NF-kB p65 represents factor-κB, Histone represents nuclear internal reference, Pro-IL-1β represents interleukin-1β, β-actin represents internal reference, C represents the effect of dioscin on the expression of autophagy-related proteins in macrophages, and D represents the effect of dioscin on ROS in macrophages. In the figure, Control represents the control group, LPS represents the model group, LPS+Dio represents the drug-treated group, and LPS+Dio+EX527 represents the inhibitor group;

[0026] Figure 7 The mouse tracheal instillation experiment detected the effect of dioscin on the dry-wet ratio of lung tissue in inflammatory acute lung injury. In the figure, "###" represents P<0.001 vs. CTR, "**" represents P<0.01 vs. LPS, and "***" represents P<0.001 vs. LPS, (n=3);

[0027] Figure 8 These are actual pictures of mouse lung tissues. In the picture, Control represents the control group, LPS represents the model group, LPS+Dio represents the drug-treated group, LPS+Dio+EX527 represents the inhibitor group, and LPS+DEX represents the positive drug group.

[0028] Fig. 9 This is a HE staining experiment to detect the effect of dioscin on acute lung injury in mice. In the figure, Control represents the control group, LPS represents the model group, LPS+Dio represents the drug group, LPS+Dio+EX527 represents the inhibitor group, and LPS+DEX represents the positive drug group. DETAILED DESCRIPTION

[0029] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0030] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0031] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0032] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.

[0033] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0034] Example 1

[0035] 1. Cell culture technology

[0036] (1) Recovery of J774A.1 cells

[0037] ① Wear a protective mask and thermal gloves correctly, heat the water bath to 37°C in advance, take out the J774A.1 cells from the liquid nitrogen tank, and thaw them in a constant temperature water bath;

[0038] ②Prepare a 15mL centrifuge tube in a clean bench, add 10mL DMEM medium, and transfer the cells to the centrifuge tube after they have thawed and mix well;

[0039] ③ Seal the centrifuge tube, centrifuge at 1000 rpm for 5 min at 4°C, transfer to a clean bench, discard the supernatant, add an appropriate amount of DMEM medium to resuspend the cells, inoculate them in a 10 cm culture dish, shake crosswise, and place in an incubator for static culture;

[0040] ④Observe the cell status after 12-24 hours, and replace the culture medium or perform cell passage according to the cell status.

[0041] (2) Cell passaging

[0042] ① Observe the cell growth status in advance, and perform cell passaging when the cell morphology is good and the number is appropriate. Wear gloves correctly, clean the cell clean bench, tilt the culture dish to make the culture solution tilt to one side, slowly aspirate the upper culture solution along the upper edge of the liquid surface, add 3mL DMEM culture medium, shake crosswise to wash the cells, aspirate in the same way, and repeat the washing twice;

[0043] ② Add an appropriate amount of culture medium and use a sterilized cell scraper to gently scrape the cells to make them fall off, from top to bottom, from the middle to both sides, and scrape each place only once to prevent cell damage;

[0044] ③ Use a pipette to blow the cells back and forth to completely disperse them. According to the experimental situation, take an appropriate amount of cell suspension into a new culture dish and add culture medium for subsequent experiments.

[0045] (3) Cell cryopreservation

[0046] ① Observe the cell status. When the cell status is good and the cell number is appropriate, wash the cells twice (the specific operation is the same as above);

[0047] ② Add an appropriate amount of culture medium, use a sterile scraper to gently scrape the cells to make them fall off, and use a pipette to mix them well and transfer them to a new sterile 15mL centrifuge tube;

[0048] ③ Seal the centrifuge tube and centrifuge it at 1000 rpm for 5 min in a 4°C constant temperature centrifuge. Aspirate the supernatant in a clean bench, observe the cell volume, add 1.5 mL of freezing solution to disperse the cells and transfer them to the freezing tube;

[0049] ④ Seal the cryotube, mark the complete information and place it in a programmed cooling box (can be wrapped in cotton instead), freeze it in a -80℃ low-temperature refrigerator for 24 hours and then move it to a liquid nitrogen tank for long-term storage.

[0050] (4) Construction of in vitro inflammation model and drug treatment methods

[0051] In vitro LPS (1 μg / mL) was used to induce J774A.1 cells to establish an inflammatory model. LPS treatment for 1 h activated SIRT1, which then induced the production of inflammation and the occurrence and development of HMGB1 acetylation, oxidative stress, and autophagy.

[0052] A blank control group, an LPS-induced group, and a dioscin (Dio)-treated group (0.1 μM, 0.3 μM, and 1 μM) were set up, and the Dio treatment time was 8 h.

[0053] 2. Western Blotting

[0054] Experimental principle: Western blotting is a technique for detecting, analyzing and quantifying target proteins. After separation by SDS-PAGE, the sample is transferred from the gel to a PVDF membrane, and specific antibodies are selected for staining against the target antigen. The position and depth of the bands are analyzed by instruments, which indirectly reflects the expression of the protein in cells or tissues.

[0055] (1) Preparation of protein samples: Cells from the control group and the dioscin (Dio)-treated group (doses were 0.1 μM, 0.3 μM, and 1 μM, respectively) were collected and lysed with total protein cell lysis buffer to extract total protein.

[0056] (2) Protein denaturation: After protein quantification, take the protein and add it to the corresponding centrifuge tube, add 5 μL loading buffer, and boil for 5 minutes.

[0057] (3) Place the boiled protein sample on SDS-PAGE gel for electrophoresis.

[0058] (4) After the electrophoresis stops, transfer the protein samples on the gel to a PVDF membrane soaked in methanol.

[0059] (5) Block the PVDF membrane in 5% skim milk at room temperature for 1 h.

[0060] (6) Primary antibody hybridization: Prepare the primary antibody in PBS-T20 at a ratio of 1:1000, incubate with the transferred PVDF membrane at 4°C for 12 h, and then wash in PBS-T20 for 30 min.

[0061] (7) Secondary antibody hybridization: The secondary antibody corresponding to the primary antibody was prepared at a ratio of 1:2000, incubated at room temperature for 1 h, and then washed in PBS-T20 for 30 min.

[0062] The results are as follows Figure 2 As shown, Western blotting confirmed that dioscin inhibited the acetylation of HMGB1 in macrophages in a dose-dependent manner. Figure 2 As shown in A, the expression of HMGB1 protein in cells was detected. Compared with the control group, LPS induced a decrease in the HMGB1 level in the nucleus of J774A.1 cells and an increase in the HMGB1 level in the cytoplasm. The dioscin treatment group was significantly improved compared with the model group. Figure 2As shown in B, the expression of SIRT1 and Acetylated-HMGB1 proteins in J774A.1 cells was detected. Compared with the control group, the Acetylated-HMGB1 in LPS-induced J774A.1 cells was significantly increased, and dioscin treatment inhibited the expression of Acetylated-HMGB1 protein in a dose-dependent manner. However, compared with the control group, the expression of SIRT1 in LPS-induced J774A.1 cells was decreased, and dioscin treatment increased its expression level.

[0063] like Figure 5 As shown in the figure, western blotting confirmed that dioscin promoted the expression of autophagy-related proteins in macrophages in a dose-dependent manner, and the expression of LC3A / B, p62 and Beclin-1 proteins in J774A.1 cells was detected. Compared with the control group, the LC3A / B and Beclin-1 in LPS-induced J774A.1 cells increased significantly, and dioscin treatment inhibited the expression of LC3A / B and Beclin-1 proteins in J774A.1 cells in a dose-dependent manner. However, compared with the control group, the expression of p62 in LPS-induced J774A.1 cells decreased, and dioscin treatment increased its expression level.

[0064] like Figure 6 As shown in the figure, protein immunoblotting confirmed that dioscin inhibited HMGB1 acetylation, oxidative stress and promoted autophagy in cells through SIRT1 to reduce inflammation. Studies have shown that there is a close connection between SIRT1 and inflammation, and inflammation may be involved in the occurrence and development of cell HMGB1 acetylation, oxidative stress and autophagy. Therefore, the SIRT1 inhibitor EX527 was used to treat J774A.1 cells to explore whether dioscin inhibits cell inflammation and HMGB1 acetylation, oxidative stress and promotes autophagy through SIRT1. Figure 6 As shown in Figure A, the expression of SIRT1, HMGB1, and Acetylated-HMGB1 proteins in J774A.1 cells was detected. Compared with the drug group, the Acetylated-HMGB1 in the J774A.1 cells treated with the inhibitor group increased significantly, and the HMGB1 in the cytoplasm of J774A.1 cells increased significantly, but the expression of SIRT1 in the J774A.1 cells treated with the inhibitor group decreased compared with the drug group. Figure 6 As shown in Figure B, the expression of NF-kB p65, p-NF-kB p65 and Pro-IL-1β proteins in J774A.1 cells was detected. Compared with the drug group, there was no significant change in NF-kB p65 in the J774A.1 cells treated with the inhibitor group, while the level of Pro-IL-1β protein increased significantly. The p-NF-kB p65 in the nucleus of J774A.1 cells also increased significantly. Figure 6 Middle C and Figure 6 As shown in D, the expression of autophagy-related proteins LC3A / B, p62 and Beclin-1 in the J774A.1 cells treated with the inhibitor group was significantly increased compared with the drug group, but the expression of P62 in the J774A.1 cells treated with the inhibitor group was decreased compared with the drug group.

[0065] 3. ELISA assay to detect the effect of Dioscin (Dio) on J774A.1 cell activity

[0066] The following operations were performed according to the instructions in the ELISA kit. The IL-1β kit, TNF-α kit and IL-16 kit were purchased from Shanghai ELISA Biotechnology Co., Ltd.

[0067] Experimental principle: Based on the principle of antigen-antibody specific binding, after adding the substrate, the substrate is catalyzed by the enzyme into a colored product. Qualitative or quantitative analysis can be performed based on the depth of color. A standard curve is drawn based on the standard product, and the absorbance of the unknown sample is substituted into the standard curve for calculation to obtain the concentration of the unknown sample.

[0068] Experimental methods:

[0069] (1) Allow the kit to equilibrate at room temperature for 0.5 h.

[0070] (2) Sample preparation: For cell samples, observe the growth status. When the cells are in good condition and have an appropriate number, start induction, add LPS and dioscin treatment, and discard the supernatant after co-culturing for a corresponding period of time. After washing with sterile PBS three times, add 1 mL of PBS to each plate of cells, scrape the cells and transfer them to a 1.5 mL centrifuge tube and centrifuge briefly. Use a syringe to remove the supernatant, add an appropriate amount of total cell protein lysis buffer according to the number of cells, and centrifuge for 30 minutes to collect the cell supernatant.

[0071] (3) Take 50 μL of sample and standard and add them to the coated plate respectively. In addition, use the standard dilution as the blank control group. Set up three replicate wells for each group.

[0072] (4) Add 100 μL of biotin-labeled antibody to each well, seal with a sealing film, and incubate in an incubator for 2 h.

[0073] (5) Shake off the liquid in the plate and tap it on trifold paper to ensure complete drying. Fill each well with 1× wash buffer (about 250 μL) and let it stand for 30 seconds before shaking off. Repeat the washing process three times.

[0074] (6) Add 100 μL of streptavidin-HRP to each well, tap the coated plate to mix the solution, seal it with a sealing film, and place it in an incubator for 30 min.

[0075] (7) Repeat the above washing process three times and add 50 μL of color developer A and B respectively. After vortexing and mixing, seal with a sealing film and incubate in the dark for 10 min. Finally, add 50 μL of stop solution to each well and immediately measure the data with a full-wavelength microplate reader and record it for subsequent analysis.

[0076] The results are as follows Figure 1 Middle A, Figure 1 Medium B and Figure 1 As shown in C, the ELISA method confirmed that dioscin inhibited the expression of inflammatory factors in LPS-induced macrophages in a dose-dependent manner. When LPS was given to induce the cell inflammation model, the secretion of three inflammatory factors, TNF-α, IL-6, and IL-1β, was significantly increased compared with the blank control group. The secretion level of inflammatory factors in the dioscin treatment group gradually decreased with the increase of dioscin dose. That is, in J774A.1 cells, dioscin can inhibit the release of inflammatory factors TNF-α, IL-6, and IL-1β.

[0077] IV. Effect of Dioscin (Dio) on the Content of ROS in Mouse J774A.1 Cells Detected by Reactive Oxygen Species Detection Kit

[0078] The following operations were performed in accordance with the instructions in the reactive oxygen species detection kit, which was purchased from Wuhan Elaruite Biotechnology Co., Ltd.

[0079] Experimental principle: DCFH-DA enters the cell and is deacetylated by the cell esterase, thereby becoming charged and better fixed in the cell. When it comes into contact with reactive oxygen species (ROS), it can be oxidized to generate fluorescent products, which can be detected and analyzed using a flow cytometer or a fluorescence microscope.

[0080] Experimental methods:

[0081] (1) Cell plating and drug treatment: When the cells are in good condition, they are inoculated into 24-well plates and divided into control group, model group, and drug treatment group according to the experimental situation. After treatment, they are cultured in an incubator.

[0082] (2) Remove the cell culture medium and wash the cells once with serum-free cell culture medium (Note: do not blow directly on the cells, otherwise the cells will fall off).

[0083] (3) Add an appropriate volume of DCFH-DA working solution, preferably 1 μL of DCFH-DA solution to fully cover the cells.

[0084] (4) Incubate the cells at 37°C in the dark for 60 min.

[0085] (5) Remove the reagent 1 working solution and wash 2-3 times with serum-free cell culture medium to fully remove the DCFH-DA that has not entered the cells.

[0086] (6) Place the sample on a glass slide and examine it directly under a fluorescence microscope.

[0087] (7) Detection wavelength setting: Select an excitation wavelength of 488 nm, set the exposure time according to the observed fluorescence intensity (reference 200 ms-600 ms), and measure all samples under the same parameters.

[0088] The results are as follows Figure 3 As shown in the figure, the reactive oxygen detection kit confirmed that dioscin inhibited the content of ROS in J774A.1 cells in a dose-dependent manner. To further explore the anti-inflammatory mechanism of dioscin, this experiment detected the changes in reactive oxygen in J774A.1 cells. DCFH-DA was incubated in the dark for 30 minutes. The intensity of green fluorescence under a fluorescence microscope was used to indicate the intensity of ROS based on the principle that DCFH-DA exhibits green fluorescence when in contact with reactive oxygen. It was found that dioscin (Dio) can reduce the content of ROS in the inflammatory cell model.

[0089] 5. The mitochondrial membrane potential detection kit was used to detect the damage of dioscin (Dio) to the mitochondrial membrane potential of mouse J774A.1 cells.

[0090] The following operations were performed in accordance with the instructions in the mitochondrial membrane potential detection kit, which was purchased from Shanghai ELISA Biotechnology Co., Ltd.

[0091] Experimental principle: In normal cells, JC-1 is mainly concentrated in the mitochondrial matrix in the form of polymers, showing red fluorescence; when mitochondria are damaged or destroyed, due to changes in membrane potential, JC-1 exists in the cytoplasm in the form of monomers, showing green fluorescence. Using a fluorescence microscope to observe the change in the color of JC-1 can reflect the change in mitochondrial membrane potential and the degree of depolarization.

[0092] Experimental methods:

[0093] (1) Cells in good condition were seeded in 6-well plates and divided into control group, model group, drug-treated group, and NAC group (positive drug group).

[0094] (2) The NAC (specific ROS inhibitor) group was compared with the drug-administered group (Dio).

[0095] (3) Add 1 mL of JC-1 staining working solution to the treated cells, tap gently around to allow the dye to fully contact the cells, and place in an incubator incubated in the dark for 15 min.

[0096] (4) Prepare JC-1 Buffer in advance according to the instructions. After incubation, slowly aspirate the supernatant and wash twice with appropriate amount of JC-1 Buffer. Add 2 mL of DMEM medium to each well and observe immediately under a fluorescence microscope.

[0097] The results are as follows Figure 4 As shown in the figure, the mitochondrial membrane potential detection kit confirmed that Dioscin (Dio) improved the damage of mitochondrial membrane potential of macrophages in a dose-dependent manner. When cells were stimulated by LPS, mitochondria were damaged, which was specifically manifested as a decrease in mitochondrial membrane potential. JC-1 can reflect the change of mitochondrial membrane potential through fluorescence color change. When the mitochondrial membrane potential is high (normal state), JC-1 will form an aggregated state, and the fluorescence will be red; when the mitochondrial membrane potential is low (damage occurs), JC-1 will be in a monomeric state, and the fluorescence will be green. When cells were incubated with JC-1 and observed under a fluorescence microscope, it was found that Dioscin (Dio) could restore the increase of mitochondrial membrane potential caused by LPS and reduce mitochondrial damage.

[0098] VI. Experimental Acute Lung Injury Model in Mice

[0099] Thirty male C57BL / 6 mice (20±2g) were purchased from the Animal Center of Yanbian University and randomly divided into a blank control group, an induced group, a high-dose dioscin (Dio) treatment group (5mg / kg), an EX527 (purchased from Aibixin Biotechnology Co., Ltd.) treatment group (10mg / kg), and a positive drug dexamethasone treatment group (5mg / kg). After one week of adaptation to the environment, except for the blank control group, the other four groups were gavage-administered, and LPS was instilled by tracheal instillation for 7 days. The mice were killed 24 hours later. The dry-wet ratio and degree of injury of the mouse lung tissue were detected.

[0100] VII. Detection of dry-wet ratio of lung tissue in mouse acute lung injury model

[0101] After the mice are dissected, a large amount of fluid will seep into the alveoli and interstitial lungs, causing the weight of the lungs to increase, while the dry weight of the lungs will not be affected. After the mice are euthanized, the whole lungs need to be dissected and weighed, and then the lungs are placed in a 65°C incubator to dry. After 24 hours, the lungs are taken out and weighed, and the lung wet / dry weight ratio is calculated. If the wet weight / dry weight (W / D) value after lung injury is significantly higher than that of the normal control group, it indicates that the mouse lungs are damaged.

[0102] The results are as follows Figure 7 As shown in the figure, the mouse tracheal instillation experiment confirmed that Dioscin (Dio) can inhibit the dry-wet ratio of lung tissue in inflammatory acute lung injury. It can be observed that compared with the control group, the dry-wet ratio of the LPS-induced model group was significantly increased, and the dry-wet ratio of the Dioscin (Dio)-treated group was decreased, and the effect was similar to that of the DEX-positive drug group.

[0103] 8. HE staining experiment to detect the pathological changes of mouse lung tissue

[0104] Experimental principle: Two dyes, namely the basic dye hematoxylin and the acid dye eosin, are used to interact with the cell nucleus and cytoplasm respectively, so that the cell's microstructure changes its refractive index through color, thus clearly presenting the cell image under the light microscope. The staining process involves both chemical reactions and physical effects.

[0105] Experimental methods:

[0106] (1) Slice preparation: Lung tissue was embedded in OCT and then sliced ​​using a freezing microtome.

[0107] (2) Fixation: Take out the slices and dry them, then fix them in 95% ethanol for 10 seconds and rinse.

[0108] (3) Staining: Soak in hematoxylin solution for 3 minutes and then rinse.

[0109] (4) Differentiation: Place in 0.5% hydrochloric acid ethanol for differentiation, then rinse for 20 seconds to turn blue.

[0110] (5) Soak in eosin solution for 30 seconds and then rinse.

[0111] (6) Dehydration: Use ethanol and xylene for dehydration.

[0112] (7) Sealing: After dehydration, the slides should be sealed with neutral resin immediately and observed under a fluorescence microscope after air drying.

[0113] The results are as follows Figure 8 As shown, the actual photos of mouse lung tissue show that compared with the control group, the degree of lung damage in the LPS-induced model group was more serious, and the degree of lung damage in the Dioscin (Dio)-administered group was significantly alleviated, and the effect was similar to that of the DEX-positive drug group.

[0114] like Fig. 9 As shown, HE staining experiments confirmed that dioscin alleviated acute lung injury in mice through SIRT1. It can be observed that compared with the control group, the LPS-induced model group showed obvious damage, and the dioscin (Dio)-administered group almost completely avoided the occurrence of this phenomenon, and the effect was similar to that of the DEX-positive drug group.

[0115] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Application of dioscin, the active ingredient of yam, in the preparation of drugs to improve acute lung injury.

2. The application according to claim 1, characterized in that: The yam active ingredient dioscin is used for treating, preventing or improving acute lung injury.

3. The application according to claim 1, characterized in that: The yam active ingredient dioscin promotes SIRT1 expression, inhibits HMGB1 acetylation, inhibits LPS-induced cellular oxidative stress, and promotes LPS-induced cell autophagy, thereby improving acute lung injury.

4. The use according to claim 3, characterized in that: The yam active ingredient dioscin can promote the expression of SIRT1 in LPS-induced macrophages in a dosed manner.

5. Use of dioscin, an active ingredient of yam as claimed in claim 1, in the preparation of a drug for treating, preventing or improving LPS-induced acute lung injury.

6. A drug for treating, preventing or improving acute lung injury, characterized in that: The invention comprises the yam active ingredient dioscin as described in claim 1.

7. Use of dioscin, an active ingredient of yam, as claimed in claim 1 in the preparation of a SIRT1 expression agonist.

8. The use according to claim 7, characterized in that: The yam active ingredient dioscin can promote the expression of SIRT1 in LPS-induced macrophages in a dosed manner.

9. A SIRT1 expression agonist, characterized in that The invention comprises the yam active ingredient dioscin as described in claim 1.

10. Use of dioscin, an active ingredient of yam, as claimed in claim 1 in preparing an inhibitor of HMGB1 acetylation in cells.